Anbio Biotechnology financial data

Symbol
NNNN on Nasdaq
Location
Frankfurt Am Main, Germany
Fiscal year end
31 December
Latest financial report
20-F - Q4 2024 - 28 Apr 2025

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.8M USD +21.4%
Accounts Receivable, after Allowance for Credit Loss, Current 1.06M USD -43.5%
Assets, Current 18.5M USD +17.7%
Assets 18.9M USD +19.7%
Accounts Payable, Current 1.63M USD +96.5%
Liabilities, Current 1.73M USD +74.2%
Liabilities 1.73M USD +74.2%
Retained Earnings (Accumulated Deficit) 17.2M USD +16%
Stockholders' Equity Attributable to Parent 17.2M USD +16%
Liabilities and Equity 18.9M USD +19.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 11.8M USD +21.4%